Genmab Q1 DARZALEX Sales Reach $3.964B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy GMAB?
Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S., as reported by J&J (JNJ), were $3.964B in the Q1. Net trade sales were $2.208M in the U.S. and $1.756M in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 27.910
Low
26.00
Averages
38.50
High
48.00
Current: 27.910
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genmab Major Shareholder Announcement
- Shareholder Stake: As of April 13, 2026, Orbis Investment Management Limited controls 3,114,318 shares in Genmab A/S, representing 4.85% of the company's share capital and voting rights, highlighting its significant role in corporate governance.
- Company Overview: Genmab is an international biotechnology firm dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, boasting over 25 years of experience and a diverse range of antibody therapeutic formats, showcasing its robust R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a strong late-stage clinical pipeline aimed at delivering transformative medicines to patients, which not only enhances the company's market competitiveness but also lays the groundwork for future revenue growth.
- Global Presence: Headquartered in Copenhagen, Denmark, Genmab has an international footprint across North America, Europe, and Asia Pacific, reflecting its strategic implementation of a global strategy to capture growth opportunities in the global biopharmaceutical market.
See More
Genmab's DARZALEX Global Sales Reach $3.96 Billion
- Strong Sales Performance: Genmab reported that its multiple myeloma therapy DARZALEX achieved worldwide net sales of $3.96 billion in Q1, with U.S. sales contributing $2.208 billion and international markets generating $1.756 billion, indicating robust global demand for the product.
- Positive Market Reaction: Genmab's stock traded approximately 2% higher during pre-market hours, reflecting investor optimism regarding the company's sales growth and further solidifying its market position in the biopharmaceutical sector.
- Product Diversification: The sales figures include both intravenous and subcutaneous formulations, with the latter marketed in the U.S. as DARZALEX FASPRO, demonstrating the company's innovation in product forms to meet diverse patient needs.
- Industry Context: Despite pressures on the healthcare sector due to disruptions in the Middle East, Genmab stands out among oversold healthcare stocks above $10 billion, showcasing its product resilience and competitive strength in the market.
See More
Genmab Reports $3.964 Billion DARZALEX® Sales in Q1 2026
- Strong Sales Performance: In Q1 2026, Genmab reported worldwide net sales of DARZALEX® totaling $3.964 billion, with $2.208 billion from the U.S. and $1.756 billion from the rest of the world, indicating robust demand and growth potential for the product in global markets.
- Royalty Revenue: Genmab benefits from royalties on DARZALEX sales through its exclusive global licensing agreement with Johnson & Johnson, which not only provides a stable revenue stream but also strengthens its market position in the biopharmaceutical sector.
- Innovative Drug Development: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines, showcasing its R&D capabilities and competitive edge in biotechnology, which is expected to drive future revenue growth.
- Global Market Presence: As an international biotechnology company, Genmab has established operations across North America, Europe, and Asia Pacific, and this global strategy enhances its market reach while providing ample opportunities for future expansion and growth.
See More
Safety Study of Rina-S and Bevacizumab Combination Therapy
- Clinical Trial Results: The RAINFOL™-01 trial demonstrated that the combination of Rina-S and bevacizumab was well-tolerated in 40 patients with advanced ovarian cancer, with no new safety signals, indicating potential for broader clinical treatment options.
- Adverse Event Analysis: Common treatment-emergent adverse events included nausea (80%), fatigue (67.5%), anemia (55%), and neutropenia (45%), providing critical safety data for future treatment regimens.
- Research Significance: Investigator Dr. Cara Mathews noted that the safety profile of Rina-S aligns with that of bevacizumab, potentially offering more effective disease control options for ovarian cancer patients, particularly in resistant cases.
- Future Development Directions: Genmab plans to further evaluate the efficacy of this combination therapy in the upcoming Phase 3 RAINFOL-04 trial, showcasing the company's ongoing commitment and innovative potential in ovarian cancer treatment.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Genmab Major Shareholder Announcement
- Shareholder Ownership: As of March 27, 2026, Orbis Investment Management Limited controls 3,205,763 shares in Genmab A/S, representing 4.99% of the company's share capital and voting rights, indicating its significant influence in corporate governance.
- Investment Management Background: Orbis Investment Management Limited is a well-known investment management firm, and its increased stake may impact Genmab's strategic decisions and market performance, reflecting investor confidence in the company's future growth.
- Company Overview: Established in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on improving the lives of cancer and serious disease patients through innovative antibody medicines, having received approvals for eight antibody drugs, showcasing its strong R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a robust late-stage clinical pipeline aimed at delivering transformative medicines to patients, and with the growing demand for biopharmaceuticals, the company's market outlook appears promising.
See More
Genmab Major Shareholder Announcement
- Shareholder Stake: As of April 13, 2026, Orbis Investment Management Limited controls 3,114,318 shares in Genmab A/S, representing 4.85% of the company's share capital and voting rights, highlighting its significant role in corporate governance.
- Company Overview: Genmab is an international biotechnology firm dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, boasting over 25 years of experience and a diverse range of antibody therapeutic formats, showcasing its robust R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a strong late-stage clinical pipeline aimed at delivering transformative medicines to patients, which not only enhances the company's market competitiveness but also lays the groundwork for future revenue growth.
- Global Presence: Headquartered in Copenhagen, Denmark, Genmab has an international footprint across North America, Europe, and Asia Pacific, reflecting its strategic implementation of a global strategy to capture growth opportunities in the global biopharmaceutical market.
See More
Genmab's DARZALEX Global Sales Reach $3.96 Billion
- Strong Sales Performance: Genmab reported that its multiple myeloma therapy DARZALEX achieved worldwide net sales of $3.96 billion in Q1, with U.S. sales contributing $2.208 billion and international markets generating $1.756 billion, indicating robust global demand for the product.
- Positive Market Reaction: Genmab's stock traded approximately 2% higher during pre-market hours, reflecting investor optimism regarding the company's sales growth and further solidifying its market position in the biopharmaceutical sector.
- Product Diversification: The sales figures include both intravenous and subcutaneous formulations, with the latter marketed in the U.S. as DARZALEX FASPRO, demonstrating the company's innovation in product forms to meet diverse patient needs.
- Industry Context: Despite pressures on the healthcare sector due to disruptions in the Middle East, Genmab stands out among oversold healthcare stocks above $10 billion, showcasing its product resilience and competitive strength in the market.
See More
Genmab Reports $3.964 Billion DARZALEX® Sales in Q1 2026
- Strong Sales Performance: In Q1 2026, Genmab reported worldwide net sales of DARZALEX® totaling $3.964 billion, with $2.208 billion from the U.S. and $1.756 billion from the rest of the world, indicating robust demand and growth potential for the product in global markets.
- Royalty Revenue: Genmab benefits from royalties on DARZALEX sales through its exclusive global licensing agreement with Johnson & Johnson, which not only provides a stable revenue stream but also strengthens its market position in the biopharmaceutical sector.
- Innovative Drug Development: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines, showcasing its R&D capabilities and competitive edge in biotechnology, which is expected to drive future revenue growth.
- Global Market Presence: As an international biotechnology company, Genmab has established operations across North America, Europe, and Asia Pacific, and this global strategy enhances its market reach while providing ample opportunities for future expansion and growth.
See More
Safety Study of Rina-S and Bevacizumab Combination Therapy
- Clinical Trial Results: The RAINFOL™-01 trial demonstrated that the combination of Rina-S and bevacizumab was well-tolerated in 40 patients with advanced ovarian cancer, with no new safety signals, indicating potential for broader clinical treatment options.
- Adverse Event Analysis: Common treatment-emergent adverse events included nausea (80%), fatigue (67.5%), anemia (55%), and neutropenia (45%), providing critical safety data for future treatment regimens.
- Research Significance: Investigator Dr. Cara Mathews noted that the safety profile of Rina-S aligns with that of bevacizumab, potentially offering more effective disease control options for ovarian cancer patients, particularly in resistant cases.
- Future Development Directions: Genmab plans to further evaluate the efficacy of this combination therapy in the upcoming Phase 3 RAINFOL-04 trial, showcasing the company's ongoing commitment and innovative potential in ovarian cancer treatment.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Genmab Major Shareholder Announcement
- Shareholder Ownership: As of March 27, 2026, Orbis Investment Management Limited controls 3,205,763 shares in Genmab A/S, representing 4.99% of the company's share capital and voting rights, indicating its significant influence in corporate governance.
- Investment Management Background: Orbis Investment Management Limited is a well-known investment management firm, and its increased stake may impact Genmab's strategic decisions and market performance, reflecting investor confidence in the company's future growth.
- Company Overview: Established in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on improving the lives of cancer and serious disease patients through innovative antibody medicines, having received approvals for eight antibody drugs, showcasing its strong R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a robust late-stage clinical pipeline aimed at delivering transformative medicines to patients, and with the growing demand for biopharmaceuticals, the company's market outlook appears promising.
See More
